Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:G16B*

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/106577USE OF NATURAL-ABUNDANCE STABLE ISOTOPES AND DNA GENOTYPING FOR IDENTIFYING BIOLOGICAL PRODUCTS
WO 28.05.2020
Int.Class G16B 25/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
25ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Appl.No PCT/US2019/061745 Applicant JASPER, John, P. Inventor JASPER, John, P.
The combined use of natural-abundance stable-isotopic analysis of bulk materials and DNA genotyping of biological materials is a highly-specific (~1 :1 x 1017) fingerprinting method for identifying such products in supply chains.
2.WO/2020/104394METHOD AND COMPUTER PROGRAM PRODUCT FOR ANALYSIS OF FETAL DNA BY MASSIVE SEQUENCING
WO 28.05.2020
Int.Class G16H 50/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
Appl.No PCT/EP2019/081688 Applicant SISTEMAS GENÓMICOS, S.L. Inventor TRIVIÑO PARDO, Juan Carlos
Method of analysis of fetal DNA by massive sequencing and computer program product to implement said method of analysis. The method is for determining the percentage of fetal DNA in a sample, for determining whether a fetus having fetal DNA is at risk of having alterations in the number of at least one chromosome and/or at least one chromosome fragment, wherein said alterations in the number of chromosomes are complete chromosomal fetal aneuploidies and said alterations in the number of chromosome fragments are partial fetal aneuploidies; and for determining the absence or presence of Y chromosome.
3.WO/2020/104539METHOD AND SYSTEM OF TARGETING EPITOPES FOR NEOANTIGEN-BASED IMMUNOTHERAPY
WO 28.05.2020
Int.Class G16B 20/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
20Allele or variant detection, e.g. single nucleotide polymorphism detection
Appl.No PCT/EP2019/081960 Applicant NEC CORPORATION Inventor MALONE, Brandon
A method of ranking epitopes derived from neoantigens as targets for personalized immunotherapy includes collecting candidate epitopes based on patient data of a cancer patient. A set of scores are calculated for each of the candidate epitopes, each of the scores in a respective one of the sets for a respective one of the candidate epitopes representing an independent measure of a likelihood of the respective one of candidate epitopes to elicit an immune response in the cancer patient. The scores in each of the sets of scores are combined into a single score for each of the candidate epitopes. The single scores for the candidate epitopes in each case reflect an overall likelihood of eliciting the immune response in the patient. The candidate epitopes are ranked using the single scores for the immunotherapy.
4.WO/2020/105058METHODS FOR MEASURING SMALL NUCLEIC ACID ABUNDANCE DIFFERENCES
WO 28.05.2020
Int.Class C12Q 1/686
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
686Polymerase chain reaction
Appl.No PCT/IL2019/051286 Applicant AZULAY, Chen Inventor AZULAY, Chen
Methods and kits for detecting and measuring small differences in amounts of a target nucleic acid sequence in a test sample as compared to a control sample by using competitive duplex qPCR are provided.
5.WO/2020/097660METHODS OF IDENTIFYING GENETIC VARIANTS
WO 22.05.2020
Int.Class G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Appl.No PCT/AU2019/000141 Applicant THE UNIVERSITY OF SYDNEY Inventor COOPER, Sandra
The present invention relates to identification of an abnormal splice site. Provided are methods of identifying an abnormal splice site. Methods of classifying the risk of abnormal splicing of a splice site are also provided. Databases for use in the methods provided herein are also disclosed.
6.WO/2020/099614SELECTION OF CANCER MUTATIONS FOR GENERATION OF A PERSONALIZED CANCER VACCINE
WO 22.05.2020
Int.Class G16B 20/50
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
50Mutagenesis
Appl.No PCT/EP2019/081428 Applicant NOUSCOM AG Inventor NICOSIA, Alfredo
The present invention relates to a method for selecting cancer neoantigens for use in a personalized vaccine. This invention relates as well to a method for constructing a vector or collection of vectors carrying the neoantigens for a personalized vaccine. This invention further relates to vector and collection of vectors comprising the personalized genetic vaccine and the use of said vectors in cancer treatment.
7.WO/2020/102261METHODS AND SYSTEMS FOR SOMATIC MUTATIONS AND USES THEREOF
WO 22.05.2020
Int.Class G16B 20/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Appl.No PCT/US2019/061036 Applicant MYRIAD GENETICS, INC. Inventor ZHARKIKH, Andrey
This invention provides methods and compositions for detecting somatic mutations in cancer cells. The methods can be used for measuring tumor mutation burden. Provided are methods for identifying and treating subjects who benefit from treatment with anticancer agents such as immune checkpoint inhibitors, methods for treating cancer in a subject, and methods for monitoring and prognosing a subject having cancer.
8.WO/2020/102608MULTIPLEXING HIGHLY EVOLVING VIRAL VARIANTS WITH SHERLOCK
WO 22.05.2020
Int.Class C12Q 1/6823
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
6823Release of bound markers
Appl.No PCT/US2019/061574 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor SABETI, Pardis
Methods for generating primers and/or probes for use in analyzing a sample which may comprise a pathogen target sequence are provided, including identifying pan-viral sets of primers and/or probes.
9.WO/2020/102419SYSTEMS AND METHODS FOR HIGH THROUGHPUT COMPOUND LIBRARY CREATION
WO 22.05.2020
Int.Class G16C 20/60
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
60In silico combinatorial chemistry
Appl.No PCT/US2019/061275 Applicant RECURSION PHARMACEUTICALS, INC. Inventor GIBSON, Chris
The disclosure provides methods and systems for identifying a subset of compounds in a plurality of compounds. The identifying includes obtaining, for each compound, a vector including a set of elements, where each element includes a measurement of a different feature of an instance of a cell context upon exposure to the compound. The identifying includes performing the obtaining for a plurality of cell contexts, to obtain a plurality of vectors for each compound across different cell contexts. The identifying includes combining the vectors for each compound to form a combined vector for each compound, thereby forming a plurality of combined vectors representing different compounds. The identifying includes pruning the plurality of compounds to the subset of compounds based on a similarity between respective combined vectors in the plurality of combined vectors corresponding to compounds in the plurality of compounds.
10.WO/2020/101037ORDER-MADE MEDICAL CORE SYSTEM
WO 22.05.2020
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
Appl.No PCT/JP2019/045092 Applicant TNP PARTNERS CORPORATION Inventor SHIMBORI, Yuki
Provided is a cell production method comprising: a step of generating a database of peptides specific to cancer cells from a cancer patient, the peptides being identified on the basis of information on the expression of gene products in the cancer cells and normal cells, wherein the database is specific to the cancer patient and includes the amino acid sequences of the peptides, information on the expression levels of proteins including the amino acid sequences, and information on the bonding ability of the peptides with respect to the human leukocyte antigen type of the cancer patient; a step of extracting an antigen peptide from the database on the basis of the expression level information and the information on the bonding ability; and a step of synthesizing the antigen peptide according to amino acid sequence information included in the database, and bringing the synthesized antigen peptide into contact with immature dendritic cells from the cancer patient to obtain mature dendritic cells that present the antigen peptide. The step of obtaining the mature dendritic cells includes: an inducing step for inducing the immature dendritic cells from mononuclear cells, or monocytes isolated from mononuclear cells, from the cancer patient; and a maturation step for bringing the induced immature dendritic cells into contact with a maturation inducer to mature the immature dendritic cells. In the maturation step, the antigen peptide is brought into contact with the immature dendritic cells 12 hours after bringing the maturation inducer into contact therewith.